Perinatal Outcomes with Insulin Glargine in Pregnancy
Author Information
Author(s): Graziano Di Cianni, Elisabetta Torlone, Cristina Lencioni, Matteo Bonomo, Alessandra Di Benedetto, Angela Napoli, Ester Vitacolonna, Domenico Mannino, Annunziata Lapolla
Primary Institution: University of Pisa
Hypothesis
Is insulin glargine safe and effective for women with pre-gestational diabetes during pregnancy?
Conclusion
Insulin glargine is safe and effective during pregnancy, with congenital malformation rates similar to those seen with traditional insulin treatments.
Supporting Evidence
- 107 Type 1 diabetic pregnancies were analyzed.
- The rate of congenital anomalies was 4.95%, similar to traditional insulin treatments.
- Glycaemic control improved during pregnancy for all women.
- No significant differences in birthweight or adverse outcomes between groups.
Takeaway
This study looked at pregnant women with diabetes using a specific insulin and found it to be safe, with no more problems than other insulins.
Methodology
A retrospective study of women with pre-gestational diabetes using insulin glargine before and during pregnancy.
Potential Biases
Potential bias due to the non-randomized nature of the study.
Limitations
The study is limited by its retrospective design and small sample size.
Participant Demographics
Women with Type 1 diabetes, mostly unplanned pregnancies.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website